Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 1.085
Filter
2.
N Engl J Med ; 389(19): 1766-1777, 2023 Nov 09.
Article in English | MEDLINE | ID: mdl-37815935

ABSTRACT

BACKGROUND: Nursing home residents are at high risk for infection, hospitalization, and colonization with multidrug-resistant organisms. METHODS: We performed a cluster-randomized trial of universal decolonization as compared with routine-care bathing in nursing homes. The trial included an 18-month baseline period and an 18-month intervention period. Decolonization entailed the use of chlorhexidine for all routine bathing and showering and administration of nasal povidone-iodine twice daily for the first 5 days after admission and then twice daily for 5 days every other week. The primary outcome was transfer to a hospital due to infection. The secondary outcome was transfer to a hospital for any reason. An intention-to-treat (as-assigned) difference-in-differences analysis was performed for each outcome with the use of generalized linear mixed models to compare the intervention period with the baseline period across trial groups. RESULTS: Data were obtained from 28 nursing homes with a total of 28,956 residents. Among the transfers to a hospital in the routine-care group, 62.2% (the mean across facilities) were due to infection during the baseline period and 62.6% were due to infection during the intervention period (risk ratio, 1.00; 95% confidence interval [CI], 0.96 to 1.04). The corresponding values in the decolonization group were 62.9% and 52.2% (risk ratio, 0.83; 95% CI, 0.79 to 0.88), for a difference in risk ratio, as compared with routine care, of 16.6% (95% CI, 11.0 to 21.8; P<0.001). Among the discharges from the nursing home in the routine-care group, transfer to a hospital for any reason accounted for 36.6% during the baseline period and for 39.2% during the intervention period (risk ratio, 1.08; 95% CI, 1.04 to 1.12). The corresponding values in the decolonization group were 35.5% and 32.4% (risk ratio, 0.92; 95% CI, 0.88 to 0.96), for a difference in risk ratio, as compared with routine care, of 14.6% (95% CI, 9.7 to 19.2). The number needed to treat was 9.7 to prevent one infection-related hospitalization and 8.9 to prevent one hospitalization for any reason. CONCLUSIONS: In nursing homes, universal decolonization with chlorhexidine and nasal iodophor led to a significantly lower risk of transfer to a hospital due to infection than routine care. (Funded by the Agency for Healthcare Research and Quality; Protect ClinicalTrials.gov number, NCT03118232.).


Subject(s)
Anti-Infective Agents, Local , Asymptomatic Infections , Chlorhexidine , Cross Infection , Nursing Homes , Povidone-Iodine , Humans , Administration, Cutaneous , Administration, Intranasal , Anti-Infective Agents, Local/administration & dosage , Anti-Infective Agents, Local/therapeutic use , Baths , Chlorhexidine/administration & dosage , Chlorhexidine/therapeutic use , Cross Infection/epidemiology , Cross Infection/prevention & control , Cross Infection/therapy , Hospitalization/statistics & numerical data , Nursing Homes/statistics & numerical data , Patient Transfer/statistics & numerical data , Povidone-Iodine/administration & dosage , Povidone-Iodine/therapeutic use , Skin Care/methods , Asymptomatic Infections/therapy
4.
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue ; 34(10): 1099-1102, 2022 Oct.
Article in Chinese | MEDLINE | ID: mdl-36473572

ABSTRACT

Extracorporeal membrane oxygenation (ECMO), as an effecitive life support technique, is widely used in patients with respiratory and/or cardiac failure. Infection, with a prevalence of approximately 21% in adult patients with ECMO, is one of the most common complications and has a significant impact on mortality. Early identification of infections, and accurate prevention and anti-infective therapies for ECMO patients can improve their survival, but there is a lack of standardized protocols for recognition, diagnosis, management, prevention and treatment of the infections. By analyzing a series of literatures on healthcare-associated infections in patients with ECMO, the epidemiology, pathogens, risk factors, diagnosis, prevention and treatment were summarized to provide a theoretical background for the early identification, diagnosis and patient management of nosocomial infections.


Subject(s)
Cross Infection , Extracorporeal Membrane Oxygenation , Humans , Cross Infection/therapy , Delivery of Health Care
5.
Curr Opin Anaesthesiol ; 35(5): 549-554, 2022 Oct 01.
Article in English | MEDLINE | ID: mdl-35943123

ABSTRACT

PURPOSE OF REVIEW: The aim of this review is to provide a practical and updated summary on healthcare-associated central nervous system infections and their management. RECENT FINDINGS: The term 'healthcare-associated ventriculitis and meningitis' has recently been coined and clinical practical guidelines have been published on the management of these nosocomial infections. Many aspects have still to be further investigated (e.g. cerebrospinal fluid biomarkers, indications for novel antibiotics, intrathecal antimicrobial regimens). SUMMARY: Clinicians should maintain a high index of suspicion for healthcare-associated central nervous system infections in patients with specific risk factors (i.e. recent neurosurgery, cerebrospinal shunts, drains or implantable devices, head/spinal traumatic events), taking into account systemic signs, and alterations in microbiological, imaging, cerebrospinal fluid findings. The diagnosis is often difficult to confirm because of reduced levels of consciousness or coma. Both Gram-positive and Gram-negative (often multidrug-resistant or even pandrug-resistant) microorganisms may be the cause. Selection of antibiotics must consider susceptibility and penetration into the central nervous system. Ineffective treatments are frequent, and mortality can reach 60%. Future research should focus on the diagnostic performance of biomarkers and on the use of novel antimicrobial regimens, especially for the treatment of difficult to treat infections.


Subject(s)
Central Nervous System Infections , Cross Infection , Anti-Bacterial Agents/therapeutic use , Central Nervous System , Central Nervous System Infections/chemically induced , Central Nervous System Infections/diagnosis , Central Nervous System Infections/therapy , Cross Infection/diagnosis , Cross Infection/therapy , Delivery of Health Care , Humans
6.
Pediatr Infect Dis J ; 41(3S): S26-S35, 2022 03 01.
Article in English | MEDLINE | ID: mdl-35134037

ABSTRACT

BACKGROUND: Clinically suspected and laboratory-confirmed bloodstream infections are frequent causes of morbidity and mortality during neonatal care. The most effective infection prevention and control interventions for neonates in low- and middle-income countries (LMIC) are unknown. AIM: To identify effective interventions in the prevention of hospital-acquired bloodstream infections in LMIC neonatal units. METHODS: Medline, PUBMED, the Cochrane Database of Systematic Reviews, EMBASE and PsychInfo (January 2003 to October 2020) were searched to identify studies reporting single or bundled interventions for prevention of bloodstream infections in LMIC neonatal units. RESULTS: Our initial search identified 5206 articles; following application of filters, 27 publications met the inclusion and Integrated Quality Criteria for the Review of Multiple Study Designs assessment criteria and were summarized in the final analysis. No studies were carried out in low-income countries, only 1 in Sub-Saharan Africa and just 2 in multiple countries. Of the 18 single-intervention studies, most targeted skin (n = 4) and gastrointestinal mucosal integrity (n = 5). Whereas emollient therapy and lactoferrin achieved significant reductions in proven neonatal infection, glutamine and mixed probiotics showed no benefit. Chlorhexidine gluconate for cord care and kangaroo mother care reduced infection in individual single-center studies. Of the 9 studies evaluating bundles, most focused on prevention of device-associated infections and achieved significant reductions in catheter- and ventilator-associated infections. CONCLUSIONS: There is a limited evidence base for the effectiveness of infection prevention and control interventions in LMIC neonatal units; bundled interventions targeting device-associated infections were most effective. More multisite studies with robust study designs are needed to inform infection prevention and control intervention strategies in low-resource neonatal units.


Subject(s)
Cross Infection/prevention & control , Developing Countries , Infant Health , Sepsis/prevention & control , Cross Infection/therapy , Evidence-Based Medicine , Humans , Infant , Infant, Newborn , Infection Control/methods , Patient Care Bundles , Sepsis/therapy
7.
J Clin Neurosci ; 97: 32-41, 2022 Mar.
Article in English | MEDLINE | ID: mdl-35033779

ABSTRACT

The incidence of healthcare-associated respiratory tract infections in non-ventilated patients (NVA-HARTI) in neurosurgical intensive care units (ICUs) is unknown. The impact of NVA-HARTI on patient outcomes and differences between NVA-HARTI and ventilator-associated healthcare-associated respiratory tract infections (VA-HARTI) are poorly understood. Our objectives were to report the incidence, hospital length of stay (LOS), ICU LOS, and mortality in NVA-HARTI patients and compare these characteristics to VA-HARTI in neurocritical care patients. This cohort study was conducted in a neurosurgical ICU in Moscow. From 2011 to 2020, all patients with an ICU LOS > 48 h were included. A competing risk model was used for survival and risk analysis. A total of 3,937 ICU admissions were analyzed. NVA-HARTI vs VA-HARTI results were as follows: cumulative incidence 7.2 (95%CI: 6.4-8.0) vs 15.4 (95%CI: 14.2-16.5) per 100 ICU admissions; incidence rate 4.2 ± 2.0 vs 9.5 ± 3.0 per 1000 patient-days in the ICU; median LOS 32 [Q1Q3: 21, 48.5] vs 46 [Q1Q3: 28, 76.5] days; median ICU LOS 15 [Q1Q3: 10, 28.75] vs 26 [Q1Q3: 17, 43] days; mortality 12.3% (95%CI: 7.9-16.8) vs 16.7% (95%CI: 13.6-19.7). The incidence of VA-HARTI decreased over ten years while NVA-HARTI incidence did not change. VA-HARTI was an independent risk factor of death, OR 1.54 (1.11-2.14), while NVA-HARTI was not. Our findings suggest that NVA-HARTI in neurocritical care patients represents a significant healthcare burden with relatively high incidence and associated poor outcomes. Unlike VA-HARTI, the incidence of NVA-HARTI remained constant despite preventive measures. This suggests that extrapolating VA-HARTI research findings to NVA-HARTI should be avoided.


Subject(s)
Cross Infection , Respiratory Tract Infections , Cohort Studies , Cross Infection/epidemiology , Cross Infection/therapy , Delivery of Health Care , Hospital Mortality , Humans , Incidence , Intensive Care Units , Length of Stay , Respiratory Tract Infections/epidemiology , Respiratory Tract Infections/therapy
8.
Isr Med Assoc J ; 23(10): 615-617, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34672440

ABSTRACT

BACKGROUND: Patients with severe coronavirus disease-2019 (COVID-19) are susceptible to superimposed infections. OBJECTIVES: To describe COVID-19 patients who presented with complications due to Candida bloodstream co-infection (candidemia) and their outcome in a single center in northern Israel (Emek Medical Center) during the second outbreak of COVID-19 in Israel (15 June 2020 to 20 September 2020). METHODS: A retrospective study of COVID-19 patients presenting with candidemia was conducted, including clinical and laboratory data. The incidence of candidemia among hospitalized COVID-19 patients was compared to a historical cohort of non-COVID-19 controls. RESULTS: Three COVID-19 patients complicated with candidemia were documented. All three patients died shortly after the detection of candidemia. Three different Candida sp. were isolated from the blood cultures: C. albicans, C. parapsilosis, and C. glabrata. The incidence of candidemia among COVID-19 patients was 0.679 episodes per 1000 hospital days. CONCLUSIONS: Our small sample suggests a much higher incidence of candidemia among COVID-19 patients compared to a historical cohort of non-COVID-19 controls. All clinicians treating COVID-19 patients in GICU should be aware of this complication.


Subject(s)
COVID-19 , Candida/isolation & purification , Candidemia , Caspofungin/administration & dosage , Coinfection , Cross Infection , Aged , Antifungal Agents/administration & dosage , COVID-19/complications , COVID-19/physiopathology , COVID-19/therapy , Candidemia/complications , Candidemia/diagnosis , Candidemia/drug therapy , Catheterization, Central Venous/methods , Coinfection/diagnosis , Coinfection/microbiology , Coinfection/therapy , Critical Care/methods , Cross Infection/diagnosis , Cross Infection/microbiology , Cross Infection/therapy , Fatal Outcome , Female , Hospitalization/statistics & numerical data , Humans , Male , Respiration, Artificial/methods , SARS-CoV-2/isolation & purification , Severity of Illness Index
9.
Viruses ; 13(8)2021 07 22.
Article in English | MEDLINE | ID: mdl-34452295

ABSTRACT

In May 2018, Wolvega Equine Hospital (WEH) experienced an EHV-1 outbreak. This outbreak caused significant economic losses and negative publicity for the hospital. How should hospitals prepare themselves for these outbreaks and prevent shedding of the virus on multiple neighboring premises? The hospital transformed most of its activities into mobile practice and the entire infected hospital population was moved to a separate remote location. The hospital was cleaned and disinfected according to the latest recommendations before reopening. Four neighboring professional equine businesses and three privately owned premises were affected by the spread of the virus from the hospital population and initiated quarantine restrictions. Equine hospitals should prepare themselves for EHV-1 outbreaks as the intake of the virus cannot be prevented. A management protocol should include public information protocols, swift client information and quarantine measures that ensure quick containment of the outbreak. Timely reopening of the hospital can be achieved by rehousing the contaminated population. It should also include good regulations with clients and a properly carried out release protocol. Equine sports organizations should establish sufficient vaccination coverage in order to decrease the frequency of EHV-1 outbreaks.


Subject(s)
Cross Infection/veterinary , Disease Outbreaks/veterinary , Herpesviridae Infections/veterinary , Herpesvirus 1, Equid , Horse Diseases/epidemiology , Hospitals, Animal , Animals , Communicable Disease Control , Cross Infection/prevention & control , Cross Infection/therapy , Female , Herpesviridae Infections/epidemiology , Herpesviridae Infections/prevention & control , Herpesviridae Infections/therapy , Horse Diseases/prevention & control , Horse Diseases/therapy , Horses , Male , Netherlands/epidemiology , Quarantine
10.
PLoS One ; 16(8): e0252793, 2021.
Article in English | MEDLINE | ID: mdl-34347776

ABSTRACT

BACKGROUND: Heterogeneity in sepsis expression is multidimensional, including highly disparate data such as the underlying disorders, infection source, causative micro-organismsand organ failures. The aim of the study is to identify clusters of patients based on clinical and biological characteristic available at patients' admission. METHODS: All patients included in a national prospective multicenter ICU cohort OUTCOMEREA and admitted for sepsis or septic shock (Sepsis 3.0 definition) were retrospectively analyzed. A hierarchical clustering was performed in a training set of patients to build clusters based on a comprehensive set of clinical and biological characteristics available at ICU admission. Clusters were described, and the 28-day, 90-day, and one-year mortality were compared with log-rank rates. Risks of mortality were also compared after adjustment on SOFA score and year of ICU admission. RESULTS: Of the 6,046 patients with sepsis in the cohort, 4,050 (67%) were randomly allocated to the training set. Six distinct clusters were identified: young patients without any comorbidities, admitted in ICU for community-acquired pneumonia (n = 1,603 (40%)); young patients without any comorbidities, admitted in ICU for meningitis or encephalitis (n = 149 (4%)); elderly patients with COPD, admitted in ICU for bronchial infection with few organ failures (n = 243 (6%)); elderly patients, with several comorbidities and organ failures (n = 1,094 (27%)); patients admitted after surgery, with a nosocomial infection (n = 623 (15%)); young patients with immunosuppressive conditions (e.g., AIDS, chronic steroid therapy or hematological malignancy) (n = 338 (8%)). Clusters differed significantly in early or late mortality (p < .001), even after adjustment on severity of organ dysfunctions (SOFA) and year of ICU admission. CONCLUSIONS: Clinical and biological features commonly available at ICU admission of patients with sepsis or septic shock enabled to set up six clusters of patients, with very distinct outcomes. Considering these clusters may improve the care management and the homogeneity of patients in future studies.


Subject(s)
Hospital Mortality , Hospitalization , Intensive Care Units , Sepsis , Adult , Age Factors , Aged , Cluster Analysis , Cross Infection/mortality , Cross Infection/therapy , Female , Humans , Male , Middle Aged , Pneumonia/therapy , Prospective Studies , Retrospective Studies , Risk Factors , Sepsis/etiology , Sepsis/mortality , Sepsis/therapy
11.
Crit Care Med ; 49(11): 1883-1894, 2021 11 01.
Article in English | MEDLINE | ID: mdl-34259454

ABSTRACT

OBJECTIVES: To describe the epidemiology of sepsis in critical care by applying the Sepsis-3 criteria to electronic health records. DESIGN: Retrospective cohort study using electronic health records. SETTING: Ten ICUs from four U.K. National Health Service hospital trusts contributing to the National Institute for Health Research Critical Care Health Informatics Collaborative. PATIENTS: A total of 28,456 critical care admissions (14,332 emergency medical, 4,585 emergency surgical, and 9,539 elective surgical). MEASUREMENTS AND MAIN RESULTS: Twenty-nine thousand three hundred forty-three episodes of clinical deterioration were identified with a rise in Sequential Organ Failure Assessment score of at least 2 points, of which 14,869 (50.7%) were associated with antibiotic escalation and thereby met the Sepsis-3 criteria for sepsis. A total of 4,100 episodes of sepsis (27.6%) were associated with vasopressor use and lactate greater than 2.0 mmol/L, and therefore met the Sepsis-3 criteria for septic shock. ICU mortality by source of sepsis was highest for ICU-acquired sepsis (23.7%; 95% CI, 21.9-25.6%), followed by hospital-acquired sepsis (18.6%; 95% CI, 17.5-19.9%), and community-acquired sepsis (12.9%; 95% CI, 12.1-13.6%) (p for comparison less than 0.0001). CONCLUSIONS: We successfully operationalized the Sepsis-3 criteria to an electronic health record dataset to describe the characteristics of critical care patients with sepsis. This may facilitate sepsis research using electronic health record data at scale without relying on human coding.


Subject(s)
Critical Care/statistics & numerical data , Cross Infection/mortality , Organ Dysfunction Scores , Sepsis/mortality , Sepsis/therapy , Severity of Illness Index , Adult , Aged , Cohort Studies , Cross Infection/therapy , Female , Humans , Intensive Care Units , Male , Middle Aged , Retrospective Studies , Shock, Septic/mortality , State Medicine
13.
Pediatr Infect Dis J ; 40(8): 746-748, 2021 08 01.
Article in English | MEDLINE | ID: mdl-33941743

ABSTRACT

Cutaneous mucormycosis in children is an opportunistic fungal infection associated with significant morbidity and mortality. We describe characteristics of 12 patients with healthcare-associated cutaneous mucormycosis at Texas Children's Hospital and results of an outbreak investigation. A definitive source was not identified. Skin lesions near medical device securement sites should raise concern for mucormycosis in patients with underlying medical conditions.


Subject(s)
Cross Infection/complications , Cross Infection/microbiology , Dermatomycoses/etiology , Dermatomycoses/microbiology , Mucormycosis/etiology , Mucormycosis/microbiology , Adolescent , Child , Child, Preschool , Cross Infection/therapy , Dermatomycoses/therapy , Disease Outbreaks , Female , Hospitals, Pediatric , Humans , Infant , Infant, Newborn , Infection Control , Male , Mucormycosis/therapy , Retrospective Studies , Rhizopus/isolation & purification , Texas/epidemiology
14.
Molecules ; 26(7)2021 Mar 26.
Article in English | MEDLINE | ID: mdl-33810292

ABSTRACT

Biofilms play an essential role in chronic and healthcare-associated infections and are more resistant to antimicrobials compared to their planktonic counterparts due to their (1) physiological state, (2) cell density, (3) quorum sensing abilities, (4) presence of extracellular matrix, (5) upregulation of drug efflux pumps, (6) point mutation and overexpression of resistance genes, and (7) presence of persister cells. The genes involved and their implications in antimicrobial resistance are well defined for bacterial biofilms but are understudied in fungal biofilms. Potential therapeutics for biofilm mitigation that have been reported include (1) antimicrobial photodynamic therapy, (2) antimicrobial lock therapy, (3) antimicrobial peptides, (4) electrical methods, and (5) antimicrobial coatings. These approaches exhibit promising characteristics for addressing the impending crisis of antimicrobial resistance (AMR). Recently, advances in the micro- and nanotechnology field have propelled the development of novel biomaterials and approaches to combat biofilms either independently, in combination or as antimicrobial delivery systems. In this review, we will summarize the general principles of clinically important microbial biofilm formation with a focus on fungal biofilms. We will delve into the details of some novel micro- and nanotechnology approaches that have been developed to combat biofilms and the possibility of utilizing them in a clinical setting.


Subject(s)
Antifungal Agents , Biocompatible Materials , Biofilms , Cross Infection/therapy , Drug Resistance, Fungal/drug effects , Fungi , Nanoparticles/therapeutic use , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Bandages , Biocompatible Materials/pharmacology , Biocompatible Materials/therapeutic use , Biofilms/drug effects , Biofilms/growth & development , Fungi/drug effects , Fungi/physiology , Humans
16.
Clin Exp Nephrol ; 25(6): 652-659, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33555454

ABSTRACT

BACKGROUND: Blood purification therapy is a treatment method, wherein many patients gather in the same space to receive regular treatments, possibly increasing the risk of contracting the coronavirus disease 2019 (COVID-19) through contact, droplet, and aerosol. We experienced a nosocomial outbreak and evaluated the clinical characteristics of COVID-19 infection in patients undergoing blood purification therapy. METHODS: We retrospectively analyzed 28 patients who underwent blood purification therapy at the dialysis center of our hospital from April 2, 2020, to April 29, 2020. Logistic regression analysis was performed to identify clinical factors related to COVID-19 for 18 patients who were tested using real-time reverse transcriptase-polymerase chain reaction (RT-PCR). RESULTS: Of the 28 patients, seven were COVID-19 positive, as confirmed by RT-PCR. The median age was 77 years, 22 patients were male (79%), four patients had acute kidney injury (14%), and six patients were bedridden (21%). All infected patients had been admitted to the wards where the nosocomial outbreak had occurred. Logistic regression analysis revealed that being bedridden (odds ratio 13.33, 95% confidence interval 1.05-169.56, p < 0.05) was significantly related to COVID-19 infection. However, the Charlson comorbidity index, receiving dialysis in the same room, and adjacency of the dialysis bed to COVID-19-positive patients before the confirmation of infection did not reveal any significant relationship. CONCLUSION: Bedridden patients admitted to nosocomial infection wards were associated with COVID-19 infection, and transmission within the dialysis center was not observed. More rigorous infection control measures need to be implemented for bedridden patients undergoing blood purification therapy.


Subject(s)
COVID-19/therapy , COVID-19/transmission , Cross Infection/therapy , Cross Infection/transmission , Hemodialysis Units, Hospital , Acute Kidney Injury/complications , Adult , Aged , Aged, 80 and over , Cohort Studies , Comorbidity , Disease Outbreaks , Female , Hospitalization , Humans , Infection Control , Male , Middle Aged , Polymerase Chain Reaction , Renal Dialysis , Retrospective Studies
17.
Crit Care Med ; 49(2): 169-187, 2021 02 01.
Article in English | MEDLINE | ID: mdl-33438970

ABSTRACT

OBJECTIVE: The first 70 years of critical care can be considered a period of "industrial revolution-like" advancement in terms of progressing the understanding and care of critical illness. Unfortunately, like the industrial revolution's impact on the environment, advancing ICU care of increasingly elderly, immunosuppressed, and debilitated individuals has resulted in a greater overall burden and complexity of nosocomial infections within modern ICUs. Given the rapid evolution of nosocomial infections, the authors provide an updated review. DATA SOURCES AND STUDY SELECTION: We searched PubMed and OVID for peer-reviewed literature dealing with nosocomial infections in the critically ill, as well as the websites of government agencies involved with the reporting and prevention of nosocomial infections. Search terms included nosocomial infection, antibiotic resistance, microbiome, antibiotics, and intensive care. DATA EXTRACTION AND DATA SYNTHESIS: Nosocomial infections in the ICU setting are evolving in multiple domains including etiologic pathogens plus novel or emerging pathogens, prevalence, host risk factors, antimicrobial resistance, interactions of the host microbiome with nosocomial infection occurrence, and understanding of pathogenesis and prevention strategies. Increasing virulence and antimicrobial resistance of nosocomial infections mandate increasing efforts toward their prevention. CONCLUSIONS: Nosocomial infections are an important determinant of outcome for patients in the ICU setting. Systematic research aimed at improving the prevention and treatment of nosocomial infections is still needed.


Subject(s)
Critical Care/organization & administration , Critical Illness/therapy , Cross Infection/therapy , Drug Resistance, Bacterial , Anti-Infective Agents, Local/therapeutic use , Cross Infection/prevention & control , Humans , Intensive Care Units/organization & administration , Risk Assessment , Risk Factors
18.
Microbiologyopen ; 10(1): e1151, 2021 01.
Article in English | MEDLINE | ID: mdl-33350604

ABSTRACT

BACKGROUND: Disturbance in the oropharyngeal microbiota is common in hospitalized patients and contributes to the development of nosocomial pneumonia. Lactiplantibacillus plantarum 299 and 299v (Lp299 and Lp299v) are probiotic bacteria with beneficial effects on the human microbiome. AIM: To investigate how Lp299 and Lp299v affect the growth of nosocomial oropharyngeal pathogens in vitro and to evaluate the efficacy in vivo when these probiotics are administered prophylactically in hospitalized patients. METHODS: The in vitro effect of Lp299 and Lp299v on nosocomial respiratory tract pathogens was evaluated using two methods, the co-culture and agar overlay. In the clinical study, patients were randomized to orally receive either probiotics or placebo twice daily during their hospital stay. Oropharyngeal swabs were analyzed at inclusion and every fourth day throughout hospitalization. FINDINGS: All tested pathogens were completely inhibited by both Lp299 and Lp299v using the agar-overlay method. In the co-culture experiment, Lp299 and Lp299v significantly (p < 0.05) reduced the growth of all pathogens except for Enterococcus faecalis co-incubated with Lp299. In the clinical study, daily oral treatment with Lp299 and Lp299v did not influence the development of disturbed oropharyngeal microbiota or nosocomial infection. Proton pump inhibitors, antibiotics, and steroid treatment were identified as risk factors for developing disturbed oropharyngeal microbiota. CONCLUSIONS: Lp299 and Lp299v inhibited pathogen growth in vitro but did not affect the oropharyngeal microbiota in vivo. The ClinicalTrials.gov Identifier for this study is NCT02303301.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacteria/growth & development , Cross Infection/therapy , Lactobacillus plantarum/metabolism , Probiotics/therapeutic use , Respiratory Tract Infections/therapy , Adult , Aged , Aged, 80 and over , Antibiosis/physiology , Female , Humans , Male , Microbiota/drug effects , Middle Aged , Oropharynx/microbiology , Placebos/administration & dosage , Respiratory Tract Infections/microbiology , Young Adult
19.
J Vasc Access ; 22(1): 34-41, 2021 Jan.
Article in English | MEDLINE | ID: mdl-32406328

ABSTRACT

BACKGROUND: Short-term peripheral venous catheter-associated bloodstream infection rates have not been systematically studied in Asian countries, and data on peripheral venous catheter-associated bloodstream infections incidence by number of short-term peripheral venous catheter days are not available. METHODS: Prospective, surveillance study on peripheral venous catheter-associated bloodstream infections conducted from 1 September 2013 to 31 May 2019 in 262 intensive care units, members of the International Nosocomial Infection Control Consortium, from 78 hospitals in 32 cities of 8 countries in the South-East Asia Region: China, India, Malaysia, Mongolia, Nepal, Philippines, Thailand, and Vietnam. For this research, we applied definition and criteria of the CDC NHSN, methodology of the INICC, and software named INICC Surveillance Online System. RESULTS: We followed 83,295 intensive care unit patients for 369,371 bed-days and 376,492 peripheral venous catheter-days. We identified 999 peripheral venous catheter-associated bloodstream infections, amounting to a rate of 2.65/1000 peripheral venous catheter-days. Mortality in patients with peripheral venous catheter but without peripheral venous catheter-associated bloodstream infections was 4.53% and 12.21% in patients with peripheral venous catheter-associated bloodstream infections. The mean length of stay in patients with peripheral venous catheter but without peripheral venous catheter-associated bloodstream infections was 4.40 days and 7.11 days in patients with peripheral venous catheter and peripheral venous catheter-associated bloodstream infections. The microorganism profile showed 67.1% were Gram-negative bacteria: Escherichia coli (22.9%), Klebsiella spp (10.7%), Pseudomonas aeruginosa (5.3%), Enterobacter spp. (4.5%), and others (23.7%). The predominant Gram-positive bacteria were Staphylococcus aureus (11.4%). CONCLUSIONS: Infection prevention programs must be implemented to reduce the incidence of peripheral venous catheter-associated bloodstream infections.


Subject(s)
Bacterial Infections/epidemiology , Catheter-Related Infections/epidemiology , Catheterization, Peripheral/adverse effects , Cross Infection/epidemiology , Vascular Access Devices/adverse effects , Asia/epidemiology , Bacterial Infections/microbiology , Bacterial Infections/mortality , Bacterial Infections/therapy , Catheter-Related Infections/microbiology , Catheter-Related Infections/mortality , Catheter-Related Infections/therapy , Catheterization, Peripheral/mortality , Cross Infection/microbiology , Cross Infection/mortality , Cross Infection/therapy , Hospital Mortality , Humans , Incidence , Infection Control , Length of Stay , Prospective Studies , Risk Assessment , Risk Factors , Time Factors , Treatment Outcome
20.
J Microbiol Immunol Infect ; 54(1): 54-60, 2021 Feb.
Article in English | MEDLINE | ID: mdl-32359943

ABSTRACT

BACKGROUND: The current outbreak of coronavirus disease 2019 (COVID-19) caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, Hubei, China, spreads across national and international borders. METHODS: We prospectively collected medical records of 14 health care workers (HCWs) who were infected with SARS-CoV-2, in neurosurgery department of Wuhan Union Hospital, China. RESULTS: Among the 14 HCWs, 12 were conformed cases, the other 2 were suspected cases. Most of them were either exposed to the two index patients or infected coworkers, without knowing they were COVID-19 patients. There were 4 male and 10 female infected HCWs in this cohort, whose mean age was 36 years (SD, 6 years). The main symptoms included myalgia or fatigue (100%), fever (86%) and dry cough (71%). On admission, 79% of infected HCWs showed leucopenia and 43% lymphopenia. Reduced complement C3 could be seen in 57% of the infected HCWs and IL-6 was significantly elevated in 86% of them. The proportion of lymphocytes subsets, concentrations of immunoglobulins, complement C4, IL-2, IL-4, IL-10, TNF-α and IFN-γ were within normal range in these 14 infected HCWs. The most frequent findings on pulmonary computed tomographic images were bilateral multifocal ground-glass opacifications (86%). CONCLUSIONS: Human-to-human transmission of COVID-19 pneumonia has occurred among HCWs, and most of these infected HCWs with confirmed COVID-19 are mild cases. Our data suggest that in the epidemic area of COVID-19, stringent and urgent surveillance and infection-control measures should be implemented to protect doctors and nurses from COVID-19 infection.


Subject(s)
COVID-19/epidemiology , Cross Infection/epidemiology , Disease Hotspot , Health Personnel , Occupational Diseases/epidemiology , Adult , Aged , COVID-19/diagnosis , COVID-19/therapy , Cross Infection/diagnosis , Cross Infection/therapy , Female , Humans , Infection Control , Infectious Disease Transmission, Patient-to-Professional , Lung/diagnostic imaging , Male , Middle Aged , Neurosurgery , Occupational Diseases/diagnosis , Occupational Diseases/therapy , Prospective Studies , Surgery Department, Hospital , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...